Also should see next-gen platform (payload/linker) presentation at same conference.
Takeda selected ADC will move more slowly, wouldn't be surprised if we don't see data until next year at AACR19.
All eyes on Wednesday 5PM...first clinical data for XMT-1536, sets the table for all science.
DS-8201 showing 60% ORR in Her2+ and 30% ORR in Her-low, those are the benchmarks for a competitive next-gen ADC in MBC.

Liked By
Spread the love. Be the first to like this post!
Recent MRSN News
- Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/03/2023 09:05:00 PM
- Mersana Therapeutics to Present at Upcoming Investor Conferences • GlobeNewswire Inc. • 02/02/2023 01:00:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 02/01/2023 01:19:18 PM
- Mersana Therapeutics Initiates Expansion Portion of UPGRADE-A Combination Clinical Trial in Platinum-Sensitive Ovarian Cancer • GlobeNewswire Inc. • 02/01/2023 01:00:00 PM
- Amended Statement of Ownership (sc 13g/a) • Edgar (US Regulatory) • 01/31/2023 07:02:46 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 01/25/2023 01:25:17 PM
- Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing Tumors • GlobeNewswire Inc. • 01/25/2023 01:00:00 PM
- Amended Statement of Ownership (sc 13g/a) • Edgar (US Regulatory) • 01/19/2023 09:07:23 PM
- Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 01/06/2023 09:05:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 01/06/2023 12:19:46 PM
- Mersana Therapeutics Provides Business Update and Announces Strategic Objectives and Expected Milestones • GlobeNewswire Inc. • 01/06/2023 12:00:18 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 12/27/2022 12:03:21 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 12/22/2022 09:23:22 PM
- Mersana Therapeutics Announces Research Collaboration and Commercial License Agreement with Merck KGaA, Darmstadt, Germany to Develop Novel Immunosynthen Antibody-Drug Conjugates • GlobeNewswire Inc. • 12/22/2022 09:05:10 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 12/16/2022 09:47:13 PM
- European Commission Designates UpRi as an Orphan Medicinal Product for the Treatment of Ovarian Cancer • GlobeNewswire Inc. • 12/14/2022 01:00:00 PM
- Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 12/02/2022 09:05:00 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 12/02/2022 09:03:03 PM
- SVB Securities Sticks to Their Buy Rating for Mersana Therapeutics (MRSN) • TipRanks • 11/10/2022 04:27:37 AM
- Robert W. Baird Remains a Buy on Mersana Therapeutics (MRSN) • TipRanks • 11/10/2022 04:16:29 AM
- Mersana Therapeutics to Present at Jefferies London Healthcare Conference • GlobeNewswire Inc. • 11/08/2022 01:00:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 11/07/2022 09:06:49 PM
- Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) • Edgar (US Regulatory) • 11/07/2022 09:03:59 PM
- Quarterly Report (10-q) • Edgar (US Regulatory) • 11/07/2022 01:49:36 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 11/07/2022 12:11:32 PM
TNRG Signs Reg A Offering Agreement • TNRG • Feb 3, 2023 10:30 AM
Trend Innovations Holding Inc. Thy News Application Review Year 2022 and Update Toward 2023 • TREN • Feb 2, 2023 2:00 PM
Goldshore Intersects 9.46 g/t Au over 7.45m in the Southwest Zone Widths of Mineralized System Expanded Significantly. • GSHRF • Feb 2, 2023 9:58 AM
Hempacco and Snoop Dogg Create Joint Venture to Launch Consumer Goods Powerhouse of Hemp and Hemp-Derived Products • HPCO • Feb 2, 2023 9:30 AM
Kona Gold Beverage, Inc Announces Record Revenue Month in January Eclipsing Half a Million Dollars for the First Time • KGKG • Feb 2, 2023 9:00 AM
BioLife Sciences Inc. (OTC: BLFE) Announces Letter of Intent for Exclusive Licensing Deal with Canadian Firm • BLFE • Feb 2, 2023 8:32 AM